Back to top

Analyst Blog

Avanir Pharmaceuticals, Inc. (AVNR - Snapshot Report) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Nuedexta.

Nuedexta is under review in the EU for the treatment of patients suffering from pseudobulbar affect (PBA). The committee has also recommended approval for two dosage strengths - 20/10 mg and 30/10 mg capsules.

In Nov 2011, Avanir’s Marketing Authorization Application (MAA) for Nuedexta was accepted by the European Medicines Agency (EMA). The application was based on controlled phase III studies of Nuedexta in patients with PBA, plus data from longer-term safety studies.

We note that Nuedexta is approved in the US where it is the first and only Food and Drug Administration (FDA)-approved treatment for PBA. Nuedexta was launched in the US in Jan 2011. Net Nuedexta revenues grew 20% sequentially to $14.9 million in the first quarter of 2013 ending on Dec 2012.

With the CHMP issuing a positive opinion, we expect Nuedexta to gain EU approval shortly.

We are encouraged by Avanir’s progress with its pipeline. In Feb 2013, Avanir completed the first of a two-stage pharmacokinetic study with AVP-786. The study assessed the candidate’s single and multiple dose pharmacokinetics.

Meanwhile, AVP-923 is being studied for four indications, namely, agitation in Alzheimer's disease (phase II ongoing), central neuropathic pain in multiple sclerosis (phase II ongoing), diabetic peripheral neuropathic pain (phase III completed) and levodopa-induced-dyskinesia in Parkinson's disease.

Avanir currently carries a Zacks Rank #4 (Sell). Companies like UCB (UCBJF) and Catalyst Pharmaceutical Partners Inc. (CPRX - Snapshot Report) carry a Zacks Rank #1 (Strong Buy). Onyx Pharmaceuticals, Inc. is also well positioned with Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%